巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02367 巨子生物

复活节星期一翌日休市 04-02 16:08:21

28.340

-0.080

-0.28%

最高28.920	最低27.980	成交量498.86万
今开28.440	昨收28.420	日振幅3.31%
总市值303.52亿	流通市值303.52亿	总股本10.71亿
成交额1.41亿	换手率0.47%	流通股本10.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":28.34,"timestamp":1775117301004,"preClose":28.42,"halted":0,"volume":4988586,"delay":0,"changeRate":-0.0028149190710767716,"floatShares":1071000000,"shares":1071000000,"eps":2.0627908884865866,"marketStatus":"复活节星期一翌日休市","change":-0.08,"latestTime":"04-02 16:08:21","open":28.44,"high":28.92,"low":27.98,"amount":141222416,"amplitude":0.033075,"askPrice":28.34,"askSize":17200,"bidPrice":28.32,"bidSize":2200,"shortable":3,"etf":0,"ttmEps":2.0627908884865866,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":1667491200000,"exchange":"SEHK","adjPreClose":28.42,"dividendRate":0.04609,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":0.9937831305648943,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02367","defaultTab":"news","newsList":[{"id":"2624650049","title":"增长失速、财富“腰斩”，医美富豪们正在失去“玻尿酸权杖”","url":"https://stock-news.laohu8.com/highlight/detail?id=2624650049","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624650049?lang=zh_cn&edition=full","pubTime":"2026-04-03 20:59","pubTimestamp":1775221178,"startTime":"0","endTime":"0","summary":"潮水退去，方知成色。2025年医美财报集体告别“高增长神话”，标志着行业正式由红利驱动的野蛮生长，步入存量博弈与逻辑重构的深度调整周期。据最新披露的业绩数据，头部企业利润出现普遍下滑。玻尿酸领域，爱美客遭遇上市后首次营收、净利双双负增长，扣非净利同比下滑超40%；昊海生科净利同比大跌40.3%。胶原蛋白赛道亦未能幸免，巨子生物录得上市后首次营收利润双降。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604033695172192.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695172192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","02367","BK1207","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197449508","title":"巨子生物3月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1197449508","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197449508?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:35","pubTimestamp":1775118948,"startTime":"0","endTime":"0","summary":"巨子生物于2026年4月2日发布3月股份变动月报表。公告显示，截至2026年3月31日，公司法定股本保持在5,000,000,000股普通股，面值每股USD 0.00001，注册资本USD 50,000，较上月底无变化。公告同时披露，曾于2025年6月13日购回的9,200,000股尚未注销，但本月并未对已发行股本造成影响。公告进一步表示，公司已确认符合香港联交所对上市公司的相关监管要求。该公告由执行董事兼联席公司秘书严鈺博签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1564","LU1997245177.USD","BK1593","BK0012","BK1583","LU0348735423.USD","02196","BK1588","IE00BPRC5H50.USD","LU2495084118.USD","02268","BK1617","LU0348783233.USD","01530","01099","LU1328615791.USD","LU2148510915.USD","06030","09688","600030","LU0405327148.USD","06821","02367","01789","HK0000165453.HKD","LU1969619763.USD","06160","BK0276","BK1100","BK1161","02228","IE00B543WZ88.USD","LU0405327494.USD","LU2399975544.HKD","LU1115378108.SGD","BK1515","LU1719994722.HKD","09926","LU2476274308.USD","03933","LU0307460666.USD","LU1303224171.USD","LU2488822045.USD","BK1147","LU0634319403.HKD","LU1770034418.SGD","BK0028","LU0348766576.USD","LU1255011170.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622028727","title":"【券商聚焦】国金证券维持巨子生物(02367)“买入”评级 指短期业绩承压但核心产品力稳固","url":"https://stock-news.laohu8.com/highlight/detail?id=2622028727","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622028727?lang=zh_cn&edition=full","pubTime":"2026-03-25 15:38","pubTimestamp":1774424333,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券发布研报指，巨子生物 2025年业绩短期承压，但核心产品力与品牌力依然稳固。报告期内，公司实现总收入人民币55.2亿元，同比基本持平；实现净利润人民币19.1亿元，同比下降7.1%。品牌可丽金期内收入人民币9.2亿元，同比增长9.2%，展现出较强韧性，增长得益于核心单品胶原大膜王成功迭代至3.0版本及线上渠道拓展。销售及经销开支同比增长2.4%至人民币20.6亿元，费用率有所提升。该行维持对巨子生物的“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977258","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119602796","title":"异动解读 | 巨子生物盘中大跌5.08%，因业绩下滑及短期舆论冲击","url":"https://stock-news.laohu8.com/highlight/detail?id=1119602796","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119602796?lang=zh_cn&edition=full","pubTime":"2026-03-23 14:12","pubTimestamp":1774246369,"startTime":"0","endTime":"0","summary":"巨子生物今日盘中大跌5.08%，引起了市场的广泛关注。消息面上，公司发布的年度业绩显示，期内实现营业收入55.19亿元，同比下降0.37%；归母净利润19.15亿元，同比下降7.15%。同时，短期舆论对公司销售造成了冲击，加之行业竞争加剧，共同影响了投资者情绪。中金发表报告指出，基于外部冲击影响及竞争加剧，下调了巨子生物2026-2027年的净利润预测，维持“跑赢行业”评级，但将目标价下调13%至49港元。东吴证券也表示，考虑到行业竞争加剧及短期舆论影响，下调了对公司未来两年的盈利预测，但维持“买入”评级，认为公司作为重组胶原蛋白领域的龙头，长期地位依然突出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621572245","title":"中金：降巨子生物(02367)目标价至49港元 维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2621572245","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621572245?lang=zh_cn&edition=full","pubTime":"2026-03-23 13:59","pubTimestamp":1774245586,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，基于外部冲击影响及竞争加剧，下调巨子生物(02367)2026-2027年净利润预测各10%、10%至19.2亿及21.5亿元人民币，维持“跑赢行业”评级，基于盈利预测及板块估值中枢变化，下调目标价13%至49港元。巨子生物2025年业绩符合该行预期。收入55.2亿元人民币，同比跌0.4%，净利润19.2亿元人民币，同比跌7.2%，经调整净利润19.6亿元人民币，同比跌8.9%，业绩符合该行预期。同时公司公布2025年末期股息每股0.54元人民币和特别股息0.67元人民币，合计分红比例67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","BK1583","06160","LU0348827113.USD","BK1500","LU1115378108.SGD","BK1574","IE00BPRC5H50.USD","LU0540923850.HKD","LU2399975544.HKD","02228","01789","01530","BK1207","LU0348784397.USD","LU0417516902.SGD","LU0634319403.HKD","09926","BK1617","02196","02268","LU1303224171.USD","BK1197","LU0348767384.USD","LU1770034418.SGD","03933","LU0417516571.SGD","LU0348735423.USD","LU2476274308.USD","LU2778985437.USD","BK1593","BK1588","LU2488822045.USD","BK1585","LU1719994722.HKD","01099","02367","LU0417516738.SGD","LU1794554557.SGD","LU2476274720.SGD","LU0348766576.USD","CXO","03329","BK1161","BK1141","BK1191","LU2328871848.SGD","LU0307460666.USD","06821","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621434857","title":"【东吴商社吴劲草团队】巨子生物 |2025年年报点评：胶原医美获批打开成长新空间，期待26年业绩回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2621434857","media":"草叔消费升级研究","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621434857?lang=zh_cn&edition=full","pubTime":"2026-03-22 20:53","pubTimestamp":1774183980,"startTime":"0","endTime":"0","summary":"主品牌表现分化：分品牌看，2025年可复美/可丽金分别实现收入44.7/9.2亿元，同比分别-1.6%/+9.2%，收入占比分别为81.0%/16.6%。盈利预测与投资评级：公司作为我国重组胶原蛋白领域的龙头，护肤领域品牌力和产品力基本盘稳固，医美领域两款新品获批上市，有望打开成长空间。短期舆论导致业绩波动，但长期公司龙头地位突出，期待26年业绩逐渐回暖，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzIwMjU2Nzg0MQ==&mid=2247556063&idx=2&sn=621b04f356970b07a103fd5ee0a5ead9&chksm=97d6a3351062c053858d0125503747c12a933193be9919f8be16d55ea75ccd84147a625d8b04&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU2488822045.USD","SG9999004311.SGD","BK1207","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620734490","title":"官宣孵化“利妍”新品牌，巨子生物“医美第一枪”如何打响？","url":"https://stock-news.laohu8.com/highlight/detail?id=2620734490","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620734490?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:04","pubTimestamp":1774015468,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者凌晨报道经历多年爆发式红利期后，重组胶原蛋白赛道正处于增速回归的转折点。3月19日，巨子生物交出了一份略显沉重的2025财年答卷。据悉，该公司全年实现营收55.18亿元，同比微降0.4%；净利润19.14亿元，同比下降7.1%。这是巨子生物上市以来首次出现营收与利润的双重失速。过去一年，巨子生物在资本市场经历了剧烈的估值重塑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603203679228390.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603203679228390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK1207","SG9999004311.SGD","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620882547","title":"花旗：料巨子生物(02367)下半年有望复苏 目标价降至37港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620882547","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620882547?lang=zh_cn&edition=full","pubTime":"2026-03-20 15:05","pubTimestamp":1773990340,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，巨子生物2025年净利润下跌7%，符合公司去年12月指引的中高个位数跌幅，并与该行预期一致。考虑到销售及利润率展望低于预期，花旗下调对巨子生物的今明两年盈利预测8%及13%，目标价由44.6港元下调至37港元，基于2026年预测市盈率18倍，估值处于低谷，料今年下半年有望复苏，维持“买入”评级。花旗预计2026年毛利率将因产品组合转变及原材料成本上升而轻微收缩。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620209291","title":"“玻胶大战”之后，巨子生物首现增长焦虑","url":"https://stock-news.laohu8.com/highlight/detail?id=2620209291","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620209291?lang=zh_cn&edition=full","pubTime":"2026-03-20 11:28","pubTimestamp":1773977308,"startTime":"0","endTime":"0","summary":"2025年中，一场与华熙生物的“行业级舆论争议”将巨子生物推上了风口浪尖。\n 这场争端不仅是重组胶原...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"14b276952a6b46a2a5e9067b5afd7fce","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3767977","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367","LU2488822045.USD","BK1207","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620541205","title":"中金：维持巨子生物(02367)“跑赢行业”评级 产品矩阵拓展下经营改善可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2620541205","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620541205?lang=zh_cn&edition=full","pubTime":"2026-03-20 09:43","pubTimestamp":1773970988,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持巨子生物“跑赢行业”评级，基于盈利预测及板块估值中枢变化，下调目标价13%至49元，对应26-27年24/22 x P/E，有59%上行空间。产品结构变化导致毛利率小幅下行品牌投入加大带动销售费率同比提升，净利率同比小幅下降。该行看好后续化妆品基本盘修复向好、医美贡献增量带来的经营改善，建议关注布局机会。风险提示行业竞争持续加剧;产品注册进展不及预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620137203","title":"巨子生物去年营收净利双降！旗下品牌可复美曾被质疑成分造假，消费者投诉屡见不鲜","url":"https://stock-news.laohu8.com/highlight/detail?id=2620137203","media":"深圳商报·读创","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620137203?lang=zh_cn&edition=full","pubTime":"2026-03-20 09:16","pubTimestamp":1773969363,"startTime":"0","endTime":"0","summary":"3月19日晚间，巨子生物（02367）发布的公告显示，该公司2025年实现收入约55.19亿元，同比减少0.4%；净利润约19.15亿元，同比下滑7.1%。据公开资料，巨子生物于2022年登陆港股，立足科技美学，聚焦功效性护肤品、医疗器械、功能性食品及特殊医学用途配方食品三大产业方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603203678303179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103943006","title":"巨子生物控股有限公司(02367)2025年度报告：营收55.185亿元，同比微降0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103943006","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103943006?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:09","pubTimestamp":1773918557,"startTime":"0","endTime":"0","summary":"巨子生物控股有限公司截至2025年12月31日止年度录得收入约55.185亿元，同比减少0.4%。期内毛利约44.334亿元，同比下降2.5%，主要由于产品组合变化及销售成本上升所致。销售成本由上年的9.919亿元升至10.852亿元，增幅9.4%，导致毛利率由82.1%下降至80.3%。董事会建议派发末期股息每股人民币0.5390元，并建议派发特别股息每股人民币0.6714元。公司于2025年12月31日维持稳健的资产负债状况，流动资金约63.062亿元，同比增加56.5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100300618","title":"巨子生物(02367)将于2026年06月25日派发特别股息每股0.6714元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100300618","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100300618?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:06","pubTimestamp":1773918393,"startTime":"0","endTime":"0","summary":"巨子生物(02367)发布公告，董事会宣派截至2025年12月31日止年度的特别股息，每股0.6714人民币，尚待股东于2026年5月28日批准。根据公告，股份除净日为2026年6月1日，为符合获派息资格而递交股份过户文件的截止时间为2026年6月2日下午4时30分。公司将于2026年6月3日至6月8日暂停办理股份过户登记手续，记录日期为2026年6月8日，预计股息派发日为2026年6月25日。公告还显示，本次股息金额及公司预设派发货币为港元，汇率有待公布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176415488","title":"巨子生物(02367)将于2026年06月25日派发末期股息每股0.539元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176415488","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176415488?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:06","pubTimestamp":1773918390,"startTime":"0","endTime":"0","summary":"巨子生物(02367)公布，董事会建议派发截至2025年12月31日止年度的末期股息，每股人民币0.539元，尚待股东于2026年5月28日批准。根据公告，股份除净日为2026年6月1日，股东需于2026年6月2日16时30分前递交过户文件。公司将于2026年6月3日至2026年6月8日暂停办理股份过户登记手续，并于2026年6月8日确定股东名册登记。股息预期于2026年6月25日派付。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244915","title":"巨子生物(02367)公布2025年业绩 归母净利润约19.15亿元 同比减少7.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620244915?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:05","pubTimestamp":1773918358,"startTime":"0","endTime":"0","summary":"智通财经APP讯，巨子生物 公布2025年业绩，收入约55.185亿元，同比减少0.4%;毛利约44.334亿元，同比减少2.5%;归属于母公司持有者盈利约19.15亿元，同比减少7.2%;经调整净利润约19.6亿元，同比减少8.9%;每股基本盈利1.83元，建议派发末期股息每股0.5390元及特别股息每股0.6714元。毛利减少主要由于销售收入的减少和销售成本的增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122278815","title":"巨子生物控股有限公司提议派发末期股息 每股普通股0.5390元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122278815","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122278815?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:03","pubTimestamp":1773918211,"startTime":"0","endTime":"0","summary":"巨子生物控股有限公司宣布，董事会提议向普通股股东派发末期股息，每股派发现金人民币0.5390元。该议案尚需提交股东大会审议批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SG9999004311.SGD","02367","BK1207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244659","title":"巨子生物(02367)将于6月25日派发特别股息每股0.6714元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244659","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620244659?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:03","pubTimestamp":1773918188,"startTime":"0","endTime":"0","summary":"智通财经APP讯，巨子生物(02367)发布公告，该公司将于2026年6月25日派发截至2025年12月31日止年度的特别股息每股0.6714元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","BK1207","LU2488822045.USD","SG9999004311.SGD","VIG","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181993530","title":"港股新消费概念股盘初走高！锅圈涨超6%，巨子生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181993530","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181993530?lang=zh_cn&edition=full","pubTime":"2026-03-17 09:42","pubTimestamp":1773711762,"startTime":"0","endTime":"0","summary":"3月17日，港股新消费概念股盘初走高，$锅圈(02517)$涨超6%，$巨子生物(02367)$涨超5%，$上美股份(02145)$涨超4%，$泡泡玛特(09992)$、$蜜雪集团(02097)$、$名创优品(09896)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"fcbc0fa50b4728616e2e43bcc93b9f2d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367","LU2488822045.USD","02517","BK4588","VXUS","BK1132","SG9999004311.SGD","BK1207","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xajuzi.com","stockEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":-0.0597},{"period":"3month","weight":-0.1718},{"period":"6month","weight":-0.4935},{"period":"1year","weight":-0.5931},{"period":"ytd","weight":-0.1484}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"巨子生物控股有限公司是一家主要从事基于生物活性成分的美丽与健康产品的研发、制造及销售业务的投资控股公司。该公司的主要产品包括功效性护肤品、医用敷料等专业皮肤护理产品，以及保健食品及其他产品。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.063759},{"month":2,"riseRate":0.75,"avgChangeRate":0.082298},{"month":3,"riseRate":0.75,"avgChangeRate":0.049732},{"month":4,"riseRate":0.75,"avgChangeRate":0.006841},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.050236},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.053764},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.046799},{"month":8,"riseRate":0.666667,"avgChangeRate":0.018731},{"month":9,"riseRate":0.666667,"avgChangeRate":0.061782},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.126143},{"month":11,"riseRate":0.333333,"avgChangeRate":0.019827},{"month":12,"riseRate":0.25,"avgChangeRate":0.047101}],"exchange":"SEHK","name":"巨子生物","nameEN":"GIANT BIOGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"巨子生物,02367,巨子生物股票,巨子生物股票老虎,巨子生物股票老虎国际,巨子生物行情,巨子生物股票行情,巨子生物股价,巨子生物股市,巨子生物股票价格,巨子生物股票交易,巨子生物股票购买,巨子生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}